Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Substituted tricyclics and method of use

A substituent, monocyclic technology applied in the field of substituted tricyclics and uses, which can solve problems such as limited treatment options

Pending Publication Date: 2022-01-11
ABBVIE INC +1
View PDF25 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The cause of the disease is thought to lie in defective protein trafficking, for which treatment options are limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted tricyclics and method of use
  • Substituted tricyclics and method of use
  • Substituted tricyclics and method of use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[1432] 1. a compound with formula (I) or a pharmaceutically acceptable salt thereof,

[1433]

[1434] in

[1435] R 1 is H or C 1 -C 3 alkyl;

[1436] X is formula (a) or formula (b)

[1437]

[1438] in

[1439] R 2A , R 2B , R 2C , and R 2D each independently hydrogen or halogen;

[1440] R 3 , R 4 , R 6 , and R 7 independently hydrogen, C 1 -C 3 alkyl, or halogen;

[1441] R 5 independently at each occurrence hydrogen, C 1 -C 3 Alkyl, C 2 -C 4 Alkenyl, or C 1 -C 3 haloalkyl;

[1442] X 1A is O or CH 2 ;

[1443] X 1B is O or CH 2 ;

[1444] Y is -G 1 , or Y is formula (c), (d), (e), (f), or (g);

[1445]

[1446] in

[1447] G 1 is phenyl or monocyclic heteroaryl, each of which is optionally followed by 1, 2 or 3 independently selected R p group substitution; where each R p independently is C 1 -C 6 Alkyl, halogen, C 1 -C 6 haloalkyl, G 2 , C 1 -C 3 Alkoxy, C 1 -C 3 Haloalkoxy, -C(O)-G A , C(O)NR A R B , or -NR A R ...

example

[2074]All reagents were commercial grade and used as received without further purification unless otherwise indicated. Commercially available anhydrous solvents were used for the reactions carried out under an inert atmosphere. Reagent grade solvents were used in all other cases unless otherwise specified. 1 The chemical shifts (δ) of the H NMR spectra are expressed relative to tetramethylsilane as an internal standard (δ 0.00) or the appropriate residual solvent peak (i.e. CHCl). 3 (δ7.27)) in parts per million (ppm). Multiplicities are given as singlet (S), doublet (d), triplet (t), quartet (q), quintet (quin), multiplet (m) and broad (br). For microwave heating The initiator is carried out.

[2075] Enantiomeric purity was determined on an Agilent HP1100 system with UV detection. Column used: ChiralpakIA (4.6×250 mm, 5 μm). Solvents used: isopropanol and tert-butyl methyl ether.

[2076] Preparative LC / MS method TFA6

[2077] Samples were analyzed by reversed-phase...

example 1

[2085] tert-Butyl 3-{6-[(2,2-difluoro-7-methyl-6,7-dihydro-2H-furo[2,3-f][1,3]benzodioxy Heterocyclopentene-7-carbonyl)amino]-3-methylpyridin-2-yl}benzoate

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Linear gradientaaaaaaaaaa
Linear gradientaaaaaaaaaa
Login to View More

Abstract

The invention relates to substituted tricyclics and a method of use. The invention provides a compound of Formula (I) in which X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjogren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Description

[0001] This application is a divisional application of Chinese patent application No. 201680053240.5 "Substituted tricyclic rings and methods of use" with an application date of July 14, 2016. [0002] CROSS-REFERENCE TO RELATED APPLICATIONS [0003] This application claims priority to US Provisional Application No. 62 / 193,391, filed July 16, 2015, and US Provisional Application No. 62 / 299,633, filed February 25, 2016, both of which are incorporated by reference for all purposes here. technical field [0004] The present invention is directed to substituted tricyclic compounds that are modulators of cystic fibrosis transmembrane conductance regulator (CFTR) proteins useful in the treatment of diseases and disorders mediated and regulated by CFTR. In addition, the present invention relates to compositions containing the compounds of the present invention and methods for their preparation. Background technique [0005] ABC transporters are a family of homologous membrane tra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D493/04C07D519/00C07D407/12A61K31/443A61K31/4439A61K31/36A61K31/501A61K31/433A61K31/4545A61K31/4436A61K31/5377A61K31/497A61K31/4433A61K31/453A61P11/00
CPCC07D493/04C07D519/00C07D407/12A61K31/443A61K31/4439A61K31/36A61K31/501A61K31/433A61K31/4545A61K31/4436A61K31/5377A61K31/497A61K31/4433A61K31/453A61P11/00C07D317/70C07D405/12A61K31/357A61K31/397A61K31/4709A61P43/00A61K45/06A61K31/404A61K31/4184A61K31/426
Inventor R.J.阿尔滕巴赫A.博丹M.D.科沃特W.R.埃斯米厄G.A.格菲泽S.N.格雷什勒J.R.克尼希P.R.凯姆刘波K.F.马拉古S.V.帕特尔M.J.斯卡尼奥X.B.瑟尔E.沃伊特王学庆M.C.杨
Owner ABBVIE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com